Guggenheim Maintains Buy on Faeth Therapeutics, Lowers Price Target to $69
Benzinga Newsdesk 6 hours ago
Analyst RatingsNewsPrice Target
Guggenheim analyst Michael Schmidt maintains Faeth Therapeutics (NASDAQ:FTH) with a Buy and lowers the price target from $70 to $69.
Guggenheim analyst Michael Schmidt maintains Faeth Therapeutics (NASDAQ:FTH) with a Buy and lowers the price target from $70 to $69.